Press release
Primary Hyperoxyaluria Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight
Primary Hyperoxyaluria Pipeline
Explore our latest breakthroughs in Primary Hyperoxyaluria Research. Learn more about our innovative pipeline today! @ Primary Hyperoxyaluria Pipeline Outlook- https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Primary Hyperoxyaluria Pipeline Report
• In November 2024:- Dicerna Pharmaceuticals, Inc., a Novo Nordisk Company- A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 11Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function. The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.
• In October 2024:- Alnylam Pharmaceuticals- A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1). The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).
• DelveInsight's Primary Hyperoxyaluria pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Primary Hyperoxyaluria treatment.
• The leading Primary Hyperoxaluria Xompanies such as Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others, are developing therapies for the Primary Hyperoxaluria treatment
• Promising Primary Hyperoxaluria therapies such as CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others.
Stay informed about the cutting-edge advancements in Primary Hyperoxyaluria treatments. Download for updates and be a part of the revolution in care @ Primary Hyperoxyaluria Clinical Trials Assessment- https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Primary Hyperoxaluria Emerging Drugs
• Oxabact: OxThera
To address Primary Hyperoxaluria (PH), OxThera has taken a bacterial strain isolated from the human gut and developed a live biotherapeutic product candidate. Oxalobacter formigenes is an anaerobe, non-pathogenic bacterium which exclusively uses oxalate as the energy source. Administration of the bacteria at pharmacological doses to PH patients is hypothezised to promote active, incremental secretion of oxalate into the gut where it is subject to degradation and enteric elimination. This highly innovative approach reroutes oxalate elimination to the gut, thereby reducing the high oxalate burden on the kidneys. Oxabact is being evalauated in Phase III stage of development for the treatment of Primary Hyperoxaluria.
Learn more about Primary Hyperoxyaluria Drugs opportunities in our groundbreaking Primary Hyperoxyaluria Research and development projects @ Primary Hyperoxyaluria Unmet Needs- https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Primary Hyperoxyaluria Companies
Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others.
Primary Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Primary Hyperoxyaluria Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Discover the latest advancements in Primary Hyperoxyaluria treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Primary Hyperoxyaluria Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Primary Hyperoxyaluria Pipeline Report
• Coverage: Global
• Primary Hyperoxaluria Companies: Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others
• Primary Hyperoxaluria Therapies: CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others
• Primary Hyperoxaluria Therapeutic Assessment: Primary Hyperoxaluria current marketed and Primary Hyperoxaluria emerging therapies
• Primary Hyperoxaluria Market Dynamics: Primary Hyperoxaluria market drivers and Primary Hyperoxaluria market barriers
For a detailed overview of our latest research findings and future plans, read the full details of Primary Hyperoxyaluria Pipeline on our website @ Primary Hyperoxyaluria Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Primary Hyperoxaluria: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Oxabact: OxThera
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Drug name: Company name
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. BBP 711: BridgeBio
14. Drug profiles in the detailed report…..
15. Preclinical stage products
16. Drug name: Company name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Primary Hyperoxaluria Key Companies
20. Primary Hyperoxaluria Key Products
21. Primary Hyperoxaluria- Unmet Needs
22. Primary Hyperoxaluria- Market Drivers and Barriers
23. Primary Hyperoxaluria- Future Perspectives and Conclusion
24. Primary Hyperoxaluria Analyst Views
25. Primary Hyperoxaluria Key Companies
26. Appendix
Trending Reports:
• Adrenal Cortex Neoplasms Market: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• Allergic Rhinitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Burkitt Lymphoma Market: https://www.delveinsight.com/report-store/burkitt-lymphoma-market
• Chronic Rhinosinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-market
• Chronic Rhinosinustis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-market
• Contraceptive Devices Market: https://www.delveinsight.com/report-store/contraceptive-devices-market
• Febrile Neutropenia Market: https://www.delveinsight.com/report-store/febrile-neutropenia-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Non-st Segment Elevation Acute Coronary Syndromes Market: https://www.delveinsight.com/report-store/non-st-segment-elevation-acute-coronary-syndromes-nste-acss-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Walking Impairment In Multiple Sclerosis Market: https://www.delveinsight.com/report-store/walking-impairment-in-multiple-sclerosis-market
• Acute On Liver Failure Market: https://www.delveinsight.com/report-store/acute-liver-failure-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Anal Cancer Market: https://www.delveinsight.com/report-store/anal-cancer-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/r-and-d-analysis
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage-gastrointestinal-cancers
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Hyperoxyaluria Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight here
News-ID: 3828700 • Views: …
More Releases from DelveInsight Business Research
Sepsis Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Sepsis pipeline constitutes 25+ key companies continuously working towards developing 30+ Sepsis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Sepsis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sepsis Market.
The Sepsis Pipeline report embraces in-depth…
Actinic Keratosis Market to Experience Notable Growth in Forecast Span by 2034, …
The Actinic Keratosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Actinic Keratosis pipeline products will significantly revolutionize the Actinic Keratosis market dynamics.
DelveInsight's "Actinic Keratosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Actinic Keratosis, historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United…
Cystinosis Market Insights Highlight Expanding Outlook Till 2032, DelveInsight E …
The Cystinosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cystinosis pipeline products will significantly revolutionize the Cystinosis market dynamics.
DelveInsight's "Cystinosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Cystinosis, historical and forecasted epidemiology as well as the Cystinosis market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Allergic Rhinitis Market to Evolve Rapidly Over the Next Decade by 2034, DelveIn …
DelveInsight's "Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Allergic Rhinitis, historical and forecasted epidemiology as well as the Allergic Rhinitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Allergic Rhinitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Allergic Rhinitis Market Forecast
https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
